FAM53C

Summary

FAM53C (family with sequence similarity 53 member C, HGNC:1336) is a protein-coding gene on chromosome 5q31.2, encoding Protein FAM53C (Q9NYF3).

The protein encoded by this gene belongs to the FAM53 protein family. FAM53 protein family members bind to a transcriptional regulator that modulates cell proliferation. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 51307 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 76 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_016605

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1336
Approved symbol	FAM53C
Name	family with sequence similarity 53 member C
Location	5q31.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000120709
Ensembl biotype	protein_coding
OMIM	609372
Entrez	51307

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 15 protein_coding, 6 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000239906, ENST00000434981, ENST00000505136, ENST00000505768, ENST00000506710, ENST00000507506, ENST00000511024, ENST00000511276, ENST00000511595, ENST00000512180, ENST00000513056, ENST00000889027, ENST00000889028, ENST00000889029, ENST00000889030, ENST00000927751, ENST00000927754, ENST00000927755, ENST00000927758, ENST00000927759, ENST00000960844, ENST00000960845

RefSeq mRNA: 4 — MANE Select: NM_016605 NM_001135647, NM_001350194, NM_001350195, NM_016605

CCDS: CCDS4204

Canonical transcript exons

ENST00000239906 — 5 exons

Exon	Start	End
ENSE00000764465	138344825	138345609
ENSE00001038703	138341184	138341413
ENSE00001937490	138346702	138349729
ENSE00002048219	138338266	138338307
ENSE00003595995	138341809	138341866

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 96.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.7232 / max 3728.7393, expressed in 1811 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58755	24.5968	1811
58754	0.0717	25
58753	0.0547	11

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	96.05	gold quality
right testis	UBERON:0004534	96.05	gold quality
blood	UBERON:0000178	95.20	gold quality
secondary oocyte	CL:0000655	94.62	gold quality
testis	UBERON:0000473	94.46	gold quality
cervix squamous epithelium	UBERON:0006922	93.88	silver quality
vastus lateralis	UBERON:0001379	93.72	gold quality
quadriceps femoris	UBERON:0001377	93.67	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	93.36	gold quality
thymus	UBERON:0002370	93.32	gold quality
gluteal muscle	UBERON:0002000	93.12	gold quality
mucosa of urinary bladder	UBERON:0001259	93.07	gold quality
tongue squamous epithelium	UBERON:0006919	92.89	silver quality
deltoid	UBERON:0001476	92.72	gold quality
oocyte	CL:0000023	92.71	gold quality
cerebellar vermis	UBERON:0004720	92.68	gold quality
diaphragm	UBERON:0001103	92.64	gold quality
skeletal muscle tissue	UBERON:0001134	92.42	gold quality
male germ cell	CL:0000015	92.34	gold quality
muscle organ	UBERON:0001630	92.34	gold quality
skeletal muscle organ	UBERON:0014892	92.34	gold quality
gastrocnemius	UBERON:0001388	92.31	gold quality
muscle of leg	UBERON:0001383	92.10	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.09	gold quality
muscle tissue	UBERON:0002385	91.93	gold quality
sperm	CL:0000019	91.86	gold quality
olfactory bulb	UBERON:0002264	91.71	silver quality
type B pancreatic cell	CL:0000169	91.52	silver quality
CA1 field of hippocampus	UBERON:0003881	91.49	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	91.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

172 targeting FAM53C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 1)

• Identification of FAM53C as a cytosolic-anchoring inhibitory binding protein of the kinase DYRK1A. (PMID:37802655)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam53c	ENSDARG00000045127
mus_musculus	Fam53c	ENSMUSG00000034300
rattus_norvegicus	Fam53c	ENSRNOG00000020261

Paralogs (2): FAM53A (ENSG00000174137), FAM53B (ENSG00000189319)

Protein

Protein identifiers

Protein FAM53C — Q9NYF3 (reviewed: Q9NYF3)

All UniProt accessions (3): D6RE00, D6RHW3, Q9NYF3

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the FAM53 family.

RefSeq proteins (4): NP_001129119, NP_001337123, NP_001337124, NP_057689* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029356	FAM53	Family

Pfam: PF15242

UniProt features (17 total): modified residue 8, region of interest 4, compositionally biased region 3, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NYF3-F1	52.63	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 162, 232, 234, 255, 273, 299, 1, 122

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 266 (showing top): FREAC2_01, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GCANCTGNY_MYOD_Q6, CMYB_01, FOXO4_01, AP2_Q3, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, GGGTGGRR_PAX4_03, CEBPB_01, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, SRF_Q5_01, GOBP_NUCLEAR_TRANSPORT, SRF_C, SOX9_B1, MYOD_01

GO Biological Process (1): protein import into nucleus (GO:0006606)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein transport	1
protein localization to nucleus	1
import into nucleus	1
establishment of protein localization to organelle	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

408 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAM53C	FAM117B	Q6P1L5	518
FAM53C	GLCCI1	Q86VQ1	467
FAM53C	DCAF7	P61962	452
FAM53C	FAM13B	Q9NYF5	447
FAM53C	RNF169	Q8NCN4	446
FAM53C	GMNN	O75496	436
FAM53C	KDM3B	Q7LBC6	419
FAM53C	EPB41	P11171	402
FAM53C	TROAP	Q12815	396
FAM53C	CYB561A3	Q8NBI2	378
FAM53C	REX1BD	Q96EN9	374
FAM53C	CREBL2	O60519	365
FAM53C	DNTTIP1	Q9H147	363
FAM53C	PAQR4	Q8N4S7	360
FAM53C	TRAPPC2L	Q9UL33	358

IntAct

121 interactions, top by confidence:

A	B	Type	Score
FAM53C	YWHAG	psi-mi:“MI:0915”(physical association)	0.880
YWHAG	FAM53C	psi-mi:“MI:0915”(physical association)	0.880
YWHAQ	WDR62	psi-mi:“MI:0914”(association)	0.830
YWHAH	ABLIM1	psi-mi:“MI:0914”(association)	0.800
YWHAB	PIK3C2A	psi-mi:“MI:0914”(association)	0.800
DCAF7	DIAPH1	psi-mi:“MI:0914”(association)	0.730
FAM53C	PLK1	psi-mi:“MI:0914”(association)	0.730
FAM53C	NCK2	psi-mi:“MI:0915”(physical association)	0.720
NCK2	FAM53C	psi-mi:“MI:0915”(physical association)	0.720
YWHAG	BLTP3B	psi-mi:“MI:0914”(association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAE	PIK3C2A	psi-mi:“MI:0914”(association)	0.570
YWHAH	BLTP3B	psi-mi:“MI:0914”(association)	0.570
YWHAZ	PIK3C2A	psi-mi:“MI:0914”(association)	0.570
DCAF7	PFDN6	psi-mi:“MI:0914”(association)	0.570
SFN	FAM53C	psi-mi:“MI:0915”(physical association)	0.560
HEL2	FAM53C	psi-mi:“MI:0915”(physical association)	0.560
FAM53C	SFN	psi-mi:“MI:0915”(physical association)	0.560
FAM53C	HEL2	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	FAM53C	psi-mi:“MI:0915”(physical association)	0.560
SORBS3	FAM53C	psi-mi:“MI:0915”(physical association)	0.560
PLK1	C1orf226	psi-mi:“MI:0914”(association)	0.560
FAM53C	FNTB	psi-mi:“MI:0914”(association)	0.530

BioGRID (110): FAM53C (Two-hybrid), FAM53C (Two-hybrid), FAM53C (Two-hybrid), FAM53C (Two-hybrid), PLK1 (Affinity Capture-MS), DYRK1B (Affinity Capture-MS), DYRK1A (Affinity Capture-MS), FNTB (Affinity Capture-MS), TRAF3 (Affinity Capture-MS), FAM53C (Affinity Capture-MS), FAM53C (Affinity Capture-MS), DYRK1B (Affinity Capture-MS), DYRK1A (Affinity Capture-MS), FNTB (Affinity Capture-MS), PLK1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GUS0, A0A5F9ZHS7, A7E346, A7MB34, A8MZG2, B2RU40, D4A9R4, O08574, O75593, P0C1Z6, P0CG20, Q0VG99, Q0ZCJ7, Q17QH7, Q29RM2, Q2KIS6, Q2M2S6, Q2M3G4, Q2NL68, Q32LE6, Q3U1J1, Q5JXC2, Q5R815, Q5SW24, Q61660, Q63247, Q6NZ36, Q6PBC9, Q6ZN01, Q6ZRI6, Q7TN08, Q7Z591, Q80VF6, Q86WR7, Q8BG26, Q8BP99, Q8BXQ8, Q8IYS4, Q8N9Y4, Q8NAV2

Diamond homologs: E9PV82, F1QN48, H2M146, Q14153, Q29RM2, Q5R815, Q5ZKN5, Q6NSI3, Q8BGR5, Q8BXQ8, Q9NYF3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 92 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	86.0×	1e-10
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	75.8×	2e-10
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	75.8×	2e-10
Activation of BH3-only proteins	7	56.1×	1e-09
RHO GTPases activate PKNs	7	35.8×	3e-08
Intrinsic Pathway for Apoptosis	7	33.1×	5e-08
FOXO-mediated transcription	5	27.1×	2e-05
SARS-CoV-1-host interactions	7	19.8×	2e-06

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	6	27.5×	2e-05
intracellular protein localization	8	10.5×	1e-04
protein phosphorylation	11	9.3×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	70
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1048 predictions. Top by Δscore:

Variant	Effect	Δscore
5:138344813:A:G	acceptor_gain	0.9900
5:138346700:A:AG	acceptor_gain	0.9900
5:138346701:G:GG	acceptor_gain	0.9900
5:138338841:G:GT	donor_gain	0.9800
5:138341807:A:AG	acceptor_gain	0.9800
5:138341808:G:GG	acceptor_gain	0.9800
5:138345605:ATCAG:A	donor_loss	0.9800
5:138345606:TCAGG:T	donor_loss	0.9800
5:138345607:CAG:C	donor_loss	0.9800
5:138345608:AG:A	donor_loss	0.9800
5:138345609:G:GC	donor_loss	0.9800
5:138345610:GTGGG:G	donor_loss	0.9800
5:138345611:T:A	donor_loss	0.9800
5:138346699:CAG:C	acceptor_loss	0.9800
5:138346700:A:G	acceptor_loss	0.9800
5:138337825:G:GA	donor_gain	0.9700
5:138338305:GCG:G	donor_gain	0.9700
5:138338314:G:GA	donor_gain	0.9700
5:138341808:GCCTT:G	acceptor_gain	0.9700
5:138344812:A:AG	acceptor_gain	0.9700
5:138345559:G:GT	donor_gain	0.9700
5:138346701:GA:G	acceptor_gain	0.9700
5:138344823:A:AG	acceptor_gain	0.9600
5:138344824:G:GG	acceptor_gain	0.9600
5:138344824:GAA:G	acceptor_gain	0.9600
5:138344906:GCC:G	donor_gain	0.9600
5:138345394:A:AG	acceptor_gain	0.9600
5:138345394:AGTCT:A	acceptor_gain	0.9600
5:138345395:G:GG	acceptor_gain	0.9600
5:138345395:GTCTG:G	acceptor_gain	0.9600

AlphaMissense

2521 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:138345602:T:C	M305T	1.000
5:138341349:T:G	I5S	0.999
5:138341361:T:C	L9P	0.999
5:138345546:G:C	K286N	0.999
5:138345546:G:T	K286N	0.999
5:138345587:T:C	L300S	0.999
5:138341349:T:A	I5N	0.998
5:138341349:T:C	I5T	0.998
5:138345033:G:C	K115N	0.998
5:138345033:G:T	K115N	0.998
5:138345040:T:C	C118R	0.998
5:138345112:T:A	W142R	0.998
5:138345112:T:C	W142R	0.998
5:138345515:G:A	C276Y	0.998
5:138345600:G:C	K304N	0.998
5:138345600:G:T	K304N	0.998
5:138345603:G:A	M305I	0.998
5:138345603:G:C	M305I	0.998
5:138345603:G:T	M305I	0.998
5:138346946:T:A	I389N	0.998
5:138345041:G:A	C118Y	0.997
5:138345042:C:G	C118W	0.997
5:138345114:G:C	W142C	0.997
5:138345114:G:T	W142C	0.997
5:138345514:T:C	C276R	0.997
5:138345544:A:G	K286E	0.997
5:138345593:T:C	F302S	0.997
5:138341346:T:C	L4P	0.996
5:138345036:G:C	R116S	0.996
5:138345036:G:T	R116S	0.996

dbSNP variants (sampled 300 via entrez): RS1000041722 (5:138348927 G>T), RS1000055010 (5:138344450 C>T), RS1000072915 (5:138349128 C>T), RS1000149974 (5:138342386 G>A), RS1000431470 (5:138338096 C>A,T), RS1000645448 (5:138338108 T>C), RS1000832738 (5:138350141 C>A,G), RS1001276510 (5:138342073 T>C), RS1001290691 (5:138349582 T>C), RS1001773868 (5:138343469 C>G), RS1001974600 (5:138343942 G>A), RS1002146652 (5:138337727 C>G), RS1002226197 (5:138350124 G>A), RS1002276134 (5:138337722 G>T), RS1002282383 (5:138337917 G>A,C,T)

Disease associations

OMIM: gene MIM:609372 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (2): autism (MONDO:0005260), autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002539_60	Schizophrenia	5.000000e-09
GCST003582_1	Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	4.000000e-08
GCST004521_66	Autism spectrum disorder or schizophrenia	1.000000e-08
GCST007201_390	Schizophrenia	2.000000e-07
GCST007201_53	Schizophrenia	1.000000e-08
GCST008103_73	Bipolar disorder	8.000000e-07
GCST008115_23	Bipolar I disorder	2.000000e-07
GCST009600_88	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	2.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009963	bipolar I disorder

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	3
cobaltous chloride	increases expression	2
Acetaminophen	increases expression	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Arsenic	affects expression, affects methylation	2
Benzo(a)pyrene	increases expression	2
Cisplatin	increases expression	2
Quercetin	decreases phosphorylation, increases expression	2
Aflatoxin B1	increases expression, increases methylation	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
trichostatin A	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sodium arsenite	increases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
K 7174	increases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
(+)-JQ1 compound	increases expression	1
PCI 5002	increases expression, affects cotreatment	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Norethindrone Acetate	affects cotreatment, increases expression	1
Atrazine	increases expression	1
Caffeine	increases phosphorylation	1
Dimethyl Sulfoxide	increases expression	1
Estradiol	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms